Dr. Changyu Zhu is an Associate Program Officer for the Helmsley Charitable Trust’s Type 1 Diabetes (T1D) Program. He helps to oversee a biomedical research grant portfolio that identifies and invests in promising therapies to delay and/or treat T1D.

Prior to joining Helmsley, Changyu was a postdoctoral researcher at Sloan Kettering Institute for Cancer Research studying cancer development and metastasis. He also conducted his doctoral thesis research at Columbia University, focusing on obesity-related metabolic diseases including fatty liver disease and diabetes.

Changyu earned a Bachelor of Science in Biology from Peking University in China, and obtained his Ph.D. degree from the Nutritional and Metabolic Biology Program from Columbia University in New York.